EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

Océane Pointeau iD, Awa Isma Ba, Audrey Geissler, Romain Barbosa, Abhishek Basu, Arif Muhammad, Marina Nivot, Maéva Loriot, Julia Leemput, Patricia Passilly-Degrace, Sébastien Causse iD, Laurent Demizieux und 9 weitere

British Journal of Pharmacology · 2025-11 · 182 (21) · 5355-5377

DOI: 10.1111/bph.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 11.07.2025. Verfasst von Océane Pointeau und 20 weiteren Autor:innen. Beteiligte Einrichtung: Université Bourgogne Europe, INSERM, Center for Translation and Molecular medicine (CTM), Team PAthophysiology of DYSlipidemia (PADYS), Dijon, France. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors, Receptor, Cannabinoid, CB1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agence Nationale de la Recherche, Université de Bourgogne, inversago pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. The cannabinoid CB 1 receptor is a potential therapeutic target. We explored combining CB 1 receptor inverse agonism and SGLT2 inhibition for treating DN, to offer better reno‐protection. Experimental approach C57BLKS‐Lepr db/db and control mice were fed a high‐protein diet for 9 weeks. After 5 weeks, db/db mice were either exposed to placebo, empagliflozin (SGLT2 inhibitor), monlunabant (CB 1 receptor inverse agonist) or a combination of both compounds (same dose) by daily oral gavage for 28 days. Diagnostic parameters for DN were analysed, along with markers of oxidative stress, inflammation and renal fibrosis. Key results Both single treatments improved albuminuria and albumin‐to‐creatinine ratios, but the combination was more effective. Similar results were seen for inflammatory oxidative stress markers. The combination showed additive protective effects on glomerular morphology, podocyte loss and proximal tubular cell injury. Dual treatment significantly reduced tubulointerstitial fibrosis compared to monotherapy and vehicle‐treated mice. Transcriptomic analysis identified the STAT3 signalling pathway as a key mediator, with decreased STAT3 phosphorylation observed with both treatments. Key mediators involved included angiopoietin 1 and fibroblast growth factor 20, which modulated the STAT3 pathway via CB 1 receptors and SGLT2, respectively. Conclusions and implications Taken together, these data strongly suggest that a poly‐pharmacological approach combining both SGLT2 inhibitors and CB 1 receptor inverse agonism represents a promising therapeutic strategy for managing DN, with better reno‐protection than mono‐therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsReceptor, Cannabinoid, CB1AnimalsMice, Inbred C57BLMiceBenzhydryl CompoundsMaleGlucosidesDisease Models, AnimalFibrosisSodium-Glucose Transporter 2

Stichwörter der Autor:innen

CB1 receptorSGLT2STAT3diabetic nephropathyempagliflozinfibrosismonlunabant

Substanzen

Sodium-Glucose Transporter 2 InhibitorsReceptor, Cannabinoid, CB1Benzhydryl CompoundsempagliflozinGlucosidesSlc5a2 protein, mouseSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Université Bourgogne Europe, INSERM, Center for Translation and Molecular medicine (CTM), Team PAthophysiology of DYSlipidemia (PADYS), Dijon, France.
  • Université Bourgogne Europe, INSERM, ImaFlow Corefacility, US58 BioSanD, Dijon, France.
  • Section on Fibrotic Disorders, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland, USA.
  • Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • INSERM 1155; Sorbonne University, Paris, France.
  • Division of Renal Transplantation, Hôpital Pitié-Salpétrière, Department of Nephrology, AP-HP, Paris, France.

ORCID-Profile: Océane Pointeau, Sébastien Causse, Hélène François, Bruno Vergès, Pascal Degrace, Resat Cinar, Tony Jourdan

Förderung

  • Agence Nationale de la Recherche
  • Université de Bourgogne
  • inversago pharma
  • European Regional Development Fund
  • Institut National de la Santé et de la Recherche Médicale
  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Pointeau, O., Ba, A. I., Geissler, A., Barbosa, R., Basu, A., Muhammad, A., Nivot, M., Loriot, M., Leemput, J., Passilly-Degrace, P., Causse, S., Demizieux, L., François, H., Vergès, B., Duan, J., Gaucher, G., Harvey, M., Degrace, P., Crater, G., …, & Jourdan, T. (2025). Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. British Journal of Pharmacology, 182(21), 5355-5377. https://doi.org/10.1111/bph.70118

Vancouver

Pointeau O, Ba AI, Geissler A, Barbosa R, Basu A, Muhammad A, et al. Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. British Journal of Pharmacology. 2025;182(21):5355-5377. doi:10.1111/bph.70118

BibTeX
@article{Pointeau2025,
  author = {Pointeau, Océane and Ba, Awa Isma and Geissler, Audrey and Barbosa, Romain and Basu, Abhishek and Muhammad, Arif and Nivot, Marina and Loriot, Maéva and Leemput, Julia and Passilly-Degrace, Patricia and Causse, Sébastien and Demizieux, Laurent and François, Hélène and Vergès, Bruno and Duan, Jianmin and Gaucher, Geneviève and Harvey, Michael and Degrace, Pascal and Crater, Glenn and Cinar, Resat and Jourdan, Tony},
  title = {Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {21},
  pages = {5355--5377},
  doi = {10.1111/bph.70118}
}
Kostenlos starten →